Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Besic, Nikola ^a   Satej, Nika ^b   Ratosa, Ivica ^a   Horvat, Andreja G ^a   Marinko, Tanja ^a   Gazic, Barbara ^a   Petric, Rok ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b Primary Healthcare Research and Development Institute   (Slovenia)

Author keywords

Breast carcinoma; Diabetes mellitus; Metformin; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; METFORMIN; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; HER 2 BREAST CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; LUMINAL A BREAST CARCINOMA; LUMINAL B BREAST CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARTIAL MASTECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREND STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; DIABETES MELLITUS; DRUG EFFECTS; FEMALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HUMANS; METFORMIN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84899922918     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-298     Document Type: Article

References (23)

1. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007, 121:856-862. 10.1002/ijc.22717, 17397032.
2. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126:215-220. 10.1007/s10549-010-1224-1, 20976543.
3. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010, 53:1631-1637. 10.1007/s00125-010-1750-8, 20407744.
4. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27:3297-3302. 10.1200/JCO.2009.19.6410, 2736070, 19487376.
5. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258. 10.2337/diacare.29.02.06.dc05-1558, 16443869.
6. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Metformin: taking away the candy for cancer?. Eur J Cancer 2010, 46:2369-2380. 10.1016/j.ejca.2010.06.012, 20656475.
7. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012, 135:821-830. 10.1007/s10549-012-2223-1, 22933030.
8. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 2012, 32:1627-1637.
9. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011, 128:783-794. 10.1007/s10549-011-1612-1, 21655990.
10. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours 2009, Oxford: Wiley-Blackwell, 7.
11. Owens WD, Felts JA, Spitznagel EL. ASA physical status classifications: a study of consistency of ratings. Anesthesiology 1978, 49:239-243. 10.1097/00000542-197810000-00003, 697077.
12. Zgajnar J, Frkovic-Grazio S, Besic N, Hocevar M, Vidergar-Kralj B, Gerljevic A, Pogacnik A. Low sensitivity of the touch imprint cytology of the sentinel lymph node in breast cancer patients-results of a large series. J Surg Oncol 2004, 85:82-86. 10.1002/jso.20011, 14755508.
13. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel members Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013, 24:2206-2223. 10.1093/annonc/mdt303, 3755334, 23917950, Panel members.
14. Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009, 16:2705-2710. 10.1245/s10434-009-0606-2, 19593632.
15. Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol 2011, 28:1260-1263. 10.1007/s12032-010-9572-6, 20490716.
16. Aksoy S, Nahit Sendur MA, Altundag K. Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Med Oncol 2013, 30:590-596.
17. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012, 30:2593-2600. 10.1200/JCO.2011.39.3769, 22564993.
18. Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumour Biol 2013, 35:2035-2045.
19. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012, 118:1202-1211. 10.1002/cncr.26439, 3207034, 21800293.
20. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 2006, 42:1077-1082. 10.1016/j.ejca.2006.01.027, 16574404.
21. Unterburger P, Sinop A, Noder W, Berger MR, Fink M, Edler L, Schmähl D, Ehrhart H. Diabetes mellitus and breast cancer. A retrospective follow-up study. Onkologie 1990, 13:17-20. 10.1159/000216712, 2186318.
22. Guastamacchia E, Resta F, Mangia A, Schittulli F, Ciampolillo A, Triggiani V, Licchelli B, Paradiso A, Sabbà C, Tafaro E. Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2003, 3:205-209. 10.2174/1568008033340199, 12871027.
23. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005, 6:103-111. 10.1016/S1470-2045(05)01736-5, 15683819.